Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
156.39
+1.31 (+0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
October 18, 2022
Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its...
Via
Benzinga
Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million
October 15, 2022
Deals, financings, trials and approvals on the China biotech/pharma market.
Via
Talk Markets
European Heath Agency's Committee Backs Approving BeiGene's Brukinsa In Leukemia Setting
October 14, 2022
Via
Benzinga
Analyst Ratings for BeiGene
October 13, 2022
Analysts have provided the following ratings for BeiGene (NASDAQ:BGNE) within the last quarter:
Via
Benzinga
BeiGene Takes On Johnson & Johnson's Blockbuster Cancer Drug — And Wins
October 12, 2022
A smaller biotech tested its experimental leukemia drug against J&J's approved med.
Via
Investor's Business Daily
BeiGene's Brukinsa Shows Superior Progression-Free Survival Versus JNJ's Treatment
October 12, 2022
Via
Benzinga
UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer
September 20, 2022
Via
Benzinga
Recap: BeiGene Q2 Earnings
August 04, 2022
BeiGene (NASDAQ:BGNE) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings BeiGene reported an EPS of $-5.56.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
October 13, 2022
Upgrades
Via
Benzinga
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
September 12, 2022
Via
Benzinga
Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay
September 09, 2022
Key Takeaways: The company logged a revenue fall of 55% in the first half of the year and posted a loss of $131 million Phase 3 clinical trials for its Covid-19 oral drug wrapped up in May but the...
Via
Benzinga
U.S.-China Audit Deal Won't Slow Hong Kong Dual Listing Train, Analysts Say
September 02, 2022
Key Takeaways: Despite a landmark U.S.-China information-sharing agreement, some predict dual listings in New York and Hong Kong will remain the preferred choice for Chinese...
Via
Benzinga
7 Chinese Stocks to Sell While You Still Can
September 02, 2022
These Chinese stocks have had a rough outing at the stock markets of late, as their underlying businesses buckle under the economic pressure
Via
InvestorPlace
Catalent, Tellurian And Other Big Losers From Monday
August 30, 2022
U.S. stocks closed lower with the Dow Jones dropping around 185 points on Monday. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday
August 30, 2022
Gainers
Via
Benzinga
Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving Premarket
August 25, 2022
Gainers ECMOHO Limited (NASDAQ: MOHO) shares rose 47% to $0.2149 in pre-market trading.
Via
Benzinga
Tesla, Autodesk And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
August 25, 2022
Snowflake Inc. (NYSE: SNOW) surged 17.4% to $187.18 in pre-market trading after the company reported better-than-expected Q2 sales results and issued product revenue guidance.
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 23, 2022
Via
Benzinga
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
August 17, 2022
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up.
Via
InvestorPlace
Recap of Tuesday's Biotech Catalysts - End Of the Day Summary
August 09, 2022
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
August 05, 2022
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
Biotech Investors: August's Key PDUFA Catalysts You Must Know
July 31, 2022
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...
Via
Benzinga
Beigene's Inspections Delay Suggest Eventual Approval, Says This Analyst
July 14, 2022
Beigene Limited (NASDAQ: BGNE) provided a regulatory update on the anticipated US approval decision for the Biological License Application for tislelizumab in 2L metastatic esophageal squamous cell...
Via
Benzinga
U.S. FDA Defers Decision On BeiGene's Filing For Esophageal Carcinoma Due To Pending Inspection
July 14, 2022
The U.S. Food and Drug Administration (FDA) has deferred decision on the Biologics License Application (BLA) for BeiGene’s (NASDAQ: BGNE) tislelizumab as a second-line treatment for patients with...
Via
Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
July 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Week In Review: Sequoia China Raises $9 Billion For Healthcare And Technology Investments
July 09, 2022
New investments in China life science may have declined over the last year, but large investment companies continue to raise large sums to invest. Sequoia China has raised about $9 billion to make...
Via
Talk Markets
Week In Review: Henlius Signs $196 Million Deal For Two Oncology Bifunctional Sialidase Candidates
July 02, 2022
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development...
Via
Talk Markets
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
July 01, 2022
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Via
Benzinga
Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study
June 30, 2022
Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.